These drugmakers have made important moves over the past year.The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure for all illnesses. Further, biotechs often deliver better-than-average financial results during economic downturns because the products they sell are considered necessary goods.Of course, not every biotech company is worth investing in. Let's consider ...

PM Images/DigitalVision via Getty Images Introduction Over the past few years, I have increasingly focused on one major issue: the looming retirement crisis. Although every time I use the word "crisis" in a title, I feel guilty of clickbait, there's no denying that it's an appropriate use of the word, as we're increasingly moving to a situation that could see significant retirement funding shortages. The Guardian headline below is a good example of this: The Guardian My most recent article on this subje ...

Amgen (AMGN) is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health, nephrology and neuroscience markets.Thousand Oaks, CA-based Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. Biosimilar drugs are also a key part of Amgen’s growth strategy. ...

Key PointsThe iShares Biotechnology ETF (IBB) is consolidating in the upper range, suggesting a potential sector breakout.Despite modest YTD gains in the biotech sector, the recent consolidation has contracted further, hinting at energy buildup for a higher breakout.The sector ETF's key holdings are Amgen (AMGN), Vertex Pharmaceuticals (VRTX), and Gilead Sciences (GILD), which influence sector direction and momentum.5 stocks we like better than Gilead SciencesThe popular iShares Biotechnology ETF NASDAQ: IB ...

Amgen (AMGN) ended the recent trading session at $283.04, demonstrating a -0.45% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.2%. Meanwhile, the Dow experienced a drop of 0.6%, and the technology-dominated Nasdaq saw an increase of 0.11%.Shares of the world's largest biotech drugmaker witnessed a gain of 1.42% over the previous month, trailing the performance of the Medical sector with its gain of 2.21% and the S&P 500's gain of 3.32%.The in ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Amgen (AMGN) , which belongs to the Zacks Medical - Biomedical and Genetics industry.This world's largest biotech drugmaker has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 3.87%.For the last reported quarter, Amgen came out with ea ...

magnetcreative/E+ via Getty Images Eli Lilly (LLY) has been a phenomenal stock to own over the past couple of years. In early 2022, it was trading for about $230 per share, but today it trades for nearly $800. This huge run is largely due to the success of its obesity drug, "Zepbound". Eli Lilly shares now trade with a whopping price to earnings ratio of around 60. Analysts expect Eli Lilly to earn about $12.47 per share, in 2024. For 2025, the earnings estimates are at $18.16, and for 2026 the estimate ...

In this articleAMGNThe Amgen logo is displayed outside Amgen headquarters on May 17, 2023 in Thousand Oaks, California.Mario Tama | Getty ImagesAmgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug.The biotech company is testing an injectable treatment that helps people lose weight differently from the existing injections from Novo Nordisk and Eli Lilly, and other obesity medicines in development. Amgen's treatment, c ...

When it comes to risk vs. reward in the stock market, the biotech sector has one of the highest potential payoffs. Many a fortune has been made after successful clinical results or a timely FDA approval for a new drug. Following a company’s progress from research to approval can be a life-changing way to invest.At the same time, biotech companies can fail during a clinical trial or get denied by the FDA. In the biotech sector, this type of failure can set a company back years or worse, send them into bankru ...

While investing in Dow stocks – that is, the 30 companies making up the Dow Jones Industrial Average – might seem incredibly boring, investors shouldn’t outright dismiss this avenue for potential profitability. I consider this segment to be the Mike Tyson of the equities market.So apparently, the former undisputed world heavyweight champion is coming out of retirement – or whatever it was that Tyson was doing – to fight YouTube celebrity Jake Paul. It might seem like a joke at first. However, I wouldn’t wan ...